TY - JOUR
T1 - Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine
T2 - A critically appraised topic
AU - Starling, Amaal J.
AU - Hoffman-Snyder, Charlene
AU - Halker, Rashmi B.
AU - Wellik, Kay E.
AU - Vargas, Bert B.
AU - Dodick, David W.
AU - Demaerschalk, Bart M.
AU - Wingerchuk, Dean M.
PY - 2011/9/1
Y1 - 2011/9/1
N2 - Background: The development of medication overuse headache (MOH) is associated with frequent use of analgesics, especially opiates, for treatment of primary headache disorders, particularly migraine. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat migraine. Objective: To critically evaluate evidence estimating the risk of MOH associated with NSAID therapy in patients with migraine. Methods: The objective was addressed through the development of a structured, critically appraised topic. This included a clinical scenario, structured question, literature search strategy, critical appraisal, results, evidence summary, commentary, and bottom line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and headache neurology content experts. Results: The 1-year incidence of MOH was 2.5%. In patients with low (0 to 4 d monthly) to moderate (5 to 9 d monthly) baseline headache frequency, NSAIDs were not associated with progression to MOH and may be protective (odds ratio=0.31; 95% confidence interval, 0.27-0.34). However, in patients with a high baseline headache frequency (10 to 14 d monthly), NSAIDs are associated with progression to MOH (odds ratio=1.93; 95% confidence interval, 1.82-2.06). Conclusions:: Acute NSAID therapy is associated with progression to MOH in migraineurs with a high baseline migraine frequency but may be protective in patients with low baseline headache frequency. However, a causal role for NSAIDs in progression from episodic to chronic headache has not been established.
AB - Background: The development of medication overuse headache (MOH) is associated with frequent use of analgesics, especially opiates, for treatment of primary headache disorders, particularly migraine. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat migraine. Objective: To critically evaluate evidence estimating the risk of MOH associated with NSAID therapy in patients with migraine. Methods: The objective was addressed through the development of a structured, critically appraised topic. This included a clinical scenario, structured question, literature search strategy, critical appraisal, results, evidence summary, commentary, and bottom line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and headache neurology content experts. Results: The 1-year incidence of MOH was 2.5%. In patients with low (0 to 4 d monthly) to moderate (5 to 9 d monthly) baseline headache frequency, NSAIDs were not associated with progression to MOH and may be protective (odds ratio=0.31; 95% confidence interval, 0.27-0.34). However, in patients with a high baseline headache frequency (10 to 14 d monthly), NSAIDs are associated with progression to MOH (odds ratio=1.93; 95% confidence interval, 1.82-2.06). Conclusions:: Acute NSAID therapy is associated with progression to MOH in migraineurs with a high baseline migraine frequency but may be protective in patients with low baseline headache frequency. However, a causal role for NSAIDs in progression from episodic to chronic headache has not been established.
KW - critically appraised topic
KW - evidence-based medicine
KW - medication overuse headache
KW - migraine disorders
KW - nonsteroidal anti-inflammatory drugs
UR - http://www.scopus.com/inward/record.url?scp=80052625573&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052625573&partnerID=8YFLogxK
U2 - 10.1097/NRL.0b013e31822d109c
DO - 10.1097/NRL.0b013e31822d109c
M3 - Article
C2 - 21881477
AN - SCOPUS:80052625573
SN - 1074-7931
VL - 17
SP - 297
EP - 299
JO - Neurologist
JF - Neurologist
IS - 5
ER -